Trial Profile
Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms RithMM
- 28 Feb 2024 Planned End Date changed from 30 Jul 2026 to 30 Sep 2024.
- 28 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2022 Planned End Date changed from 1 Mar 2021 to 30 Jul 2026.